Retrospective 72 pediatric patients showing HCQ associated with a shorter duration of fever (p
=0.023), less progression (p
=0.016), and fewer return visits to the ER (p
López et al., 11/2/2020, retrospective, Spain, Europe, peer-reviewed, 7 authors.
risk of disease progression, 64.3% lower, RR 0.36, p = 0.02, treatment 5 of 36 (13.9%), control 14 of 36 (38.9%).
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.